Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

5,206 studies for “Merck”

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)Recruiting
NCT06890884Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Lymphoma, Large B-Cell, Diffuse
United States, Belgium, Germany, Ireland, Israel +4 more
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)Recruiting
NCT06925737Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Prostate Cancer · Prostatic Neoplasms
United States, Argentina, Australia, Austria, Brazil +30 more
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)Recruiting
NCT07463183Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Colitis Ulcerative · Ulcerative Colitis
United States, Colombia, France, Greece, Netherlands +3 more
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Recruiting
NCT07227597Phase 1, Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Small Cell Lung Cancer Extensive Stage
United States, Argentina, Chile, China, Germany +7 more
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).Terminated
NCT04949256Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Esophageal Squamous Cell Carcinoma
United States, Argentina, Canada, Chile, China +20 more
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)Recruiting
NCT07133633Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Radiographic Axial Spondyloarthritis
United States, Brazil, Canada, Chile, China +9 more
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)Recruiting
NCT07634471Phase 2, Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Follicular Lymphoma
United States, Argentina, Australia, Israel, Spain +2 more
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)Recruiting
NCT07221474Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Squamous Non-small Cell Lung Cancer
United States, Argentina, Australia, Chile, France +6 more
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)Recruiting
NCT07209111Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Neoplasm Malignant
United States, Australia, Canada, Chile, China +14 more
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruiting
NCT06172478Phase 2Updated Aug 21, 2026
Sponsor: Daiichi Sankyo
Advanced Solid Tumor · Melanoma · Head and Neck Cancer · Gastric Cancer
United States, Australia, Belgium, Canada, China +11 more
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)Recruiting
NCT04728893Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Hematologic Malignancies · Waldenstroms Macroglobulinaemia · Non-Hodgkins Lymphoma · Chronic Lymphocytic Leukaemia
United States, Argentina, Australia, Brazil, Canada +17 more
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate VaccinesRecruiting
NCT07135453Phase 4Updated Aug 21, 2026
Sponsor: University of Alabama at Birmingham
Vaccine · Pneumococcal Disease
United States
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)Recruiting
NCT05714085Phase 2, Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Heart Failure · Left Ventricular Systolic Dysfunction
United States, Belgium, Brazil, Canada, Colombia +25 more
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)Recruiting
NCT07218029Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
United States, Argentina, Australia, Belgium, Brazil +22 more
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)Recruiting
NCT07190248Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Recruiting
NCT07318558Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Neoplasms · Ovarian Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)Recruiting
NCT06312137Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)Active Not Recruiting
NCT05458297Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma · Follicular Lymphoma · Richter Transformation Lymphoma
United States, Brazil, Canada, Chile, China +16 more
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)Recruiting
NCT07058077Phase 2, Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Heterozygous Familial Hypercholesterolemia (HeFH)
United States, Australia, Belgium, Brazil, Chile +11 more
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)Completed
NCT03940703Phase 2Updated Aug 21, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Non-small Cell Lung Cancer
United States, Belgium, China, France, Germany +12 more
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).Recruiting
NCT05947851Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Chronic Lymphocytic · Small-Cell Lymphoma · Lymphoma, Small Lymphocytic
United States, Argentina, Australia, Belgium, Brazil +13 more
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)Recruiting
NCT07554339Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Brazil, China +9 more
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung CancerActive Not Recruiting
NCT04699123Phase 2Updated Aug 21, 2026
Sponsor: Yale University
Advanced Non-small Cell Lung Cancer
United States
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)Recruiting
NCT05139017Phase 2, Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
DLBCL · Diffuse Large B-Cell Lymphoma
United States, Argentina, Australia, Brazil, Canada +21 more
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Recruiting
NCT07513376Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Australia, Canada, France, Germany +11 more

5,206 studies found